Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Akanda Corp (AKAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: AKAN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.13% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.30M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.5 | 52 Weeks Range 0.93 - 5.08 | Updated Date 06/29/2025 |
52 Weeks Range 0.93 - 5.08 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -564.33% |
Management Effectiveness
Return on Assets (TTM) -32.7% | Return on Equity (TTM) -1460.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -185776 | Price to Sales(TTM) 3.94 |
Enterprise Value -185776 | Price to Sales(TTM) 3.94 | ||
Enterprise Value to Revenue 3.2 | Enterprise Value to EBITDA -0.8 | Shares Outstanding 2275900 | Shares Floating 2257628 |
Shares Outstanding 2275900 | Shares Floating 2257628 | ||
Percent Insiders 0.8 | Percent Institutions 0.51 |
Upturn AI SWOT
Akanda Corp
Company Overview
History and Background
Akanda Corp. is a biotechnology company focused on developing and commercializing cannabis-based therapeutics. Founded in 2017, the company aims to leverage the therapeutic potential of cannabis for various medical conditions, particularly those underserved by traditional treatments. Significant milestones include securing funding rounds and advancing its research pipeline.
Core Business Areas
- Cannabis Therapeutics Research & Development: Akanda Corp. is actively engaged in research and development to identify, isolate, and formulate active compounds from cannabis for therapeutic applications. This includes preclinical studies and planning for clinical trials.
- Product Development and Commercialization: The company plans to develop and commercialize a range of cannabis-based pharmaceutical products, targeting specific medical indications. This involves regulatory approvals and market entry strategies.
Leadership and Structure
Akanda Corp. is led by a management team with expertise in biotechnology, pharmaceuticals, and business development. The organizational structure is typical for a growing biotech firm, with departments focused on R&D, clinical affairs, regulatory affairs, and business operations.
Top Products and Market Share
Key Offerings
- Description: AK-001 is a proprietary cannabinoid-based formulation currently in preclinical development, intended to address neuropathic pain. Market share data is not yet available as the product is in early-stage development. Competitors in the pain management market include traditional pharmaceutical companies and other emerging cannabis-based therapeutics developers.
- Product Name: AK-001 (Hypothetical)
- Description: AK-002 is another cannabinoid compound being investigated for its potential in treating inflammatory conditions. Similar to AK-001, market share is not established at this stage. Competitors include established pharmaceutical companies with anti-inflammatory drugs and other biotechs exploring similar avenues.
- Product Name: AK-002 (Hypothetical)
Market Dynamics
Industry Overview
The global cannabis therapeutics market is a rapidly evolving sector driven by increasing legalization, growing awareness of cannabis's medical potential, and demand for novel treatment options. It is characterized by significant scientific research, regulatory hurdles, and diverse market participants.
Positioning
Akanda Corp. positions itself as a science-first biotechnology company dedicated to unlocking the therapeutic value of cannabis through rigorous research and development. Its competitive advantage lies in its scientific approach, focus on specific therapeutic areas, and potential for novel product development.
Total Addressable Market (TAM)
The Total Addressable Market for cannabis-based therapeutics is substantial and growing, with estimates varying widely based on the specific indications addressed and global market penetration. Akanda Corp. aims to capture a segment of this market by developing differentiated and scientifically validated products.
Upturn SWOT Analysis
Strengths
- Focus on scientific rigor and R&D.
- Potential for novel drug development.
- Experienced management team in biotech.
- Growing global acceptance of cannabis for medical use.
Weaknesses
- Early-stage company with unproven products.
- Reliance on ongoing funding and investment.
- Regulatory uncertainties in the cannabis industry.
- Limited brand recognition compared to established pharmaceutical companies.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships with larger pharmaceutical firms.
- Advancements in cannabis research and extraction technologies.
- Increasing global regulatory pathways for cannabis medicines.
Threats
- Intense competition from established and emerging players.
- Stringent and evolving regulatory landscape.
- Public perception and stigma associated with cannabis.
- Challenges in clinical trial success and FDA approval.
Competitors and Market Share
Key Competitors
- Tilray Brands (TLRY)
- Canopy Growth Corporation (CGC)
- Aurora Cannabis Inc. (ACB)
- Cronos Group Inc. (CRON)
- GW Pharmaceuticals (acquired by Jazz Pharmaceuticals - JAZZ)
Competitive Landscape
Akanda Corp. faces a highly competitive landscape dominated by larger, more established cannabis companies and pharmaceutical giants entering the space. Its advantages lie in its specialized focus and scientific approach, but it must overcome the scale and market penetration of its rivals.
Growth Trajectory and Initiatives
Historical Growth: Akanda Corp.'s historical growth has been driven by its progress in R&D, securing funding, and building its scientific and operational infrastructure. This is typical for a biotech firm in its early stages.
Future Projections: Future projections for Akanda Corp. are heavily reliant on the success of its drug development pipeline, regulatory approvals, and market adoption of its therapies. Analyst estimates would focus on potential future revenue streams once products are commercialized.
Recent Initiatives: Recent initiatives likely involve advancing preclinical studies, forging strategic partnerships, and navigating the regulatory landscape for cannabis-based therapeutics.
Summary
Akanda Corp. is an emerging biotechnology company focused on cannabis therapeutics. While it possesses a strong scientific foundation and operates in a growing market, it faces significant challenges from established competitors, regulatory hurdles, and the need for substantial funding. Success hinges on the validation and commercialization of its drug pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website (hypothetical)
- Industry reports (general)
- Financial news outlets (general)
Disclaimers:
This JSON output is a hypothetical representation based on general knowledge of the biotechnology and cannabis industries. Specific financial data, product details, and market share for Akanda Corp. may vary and require direct consultation of company filings and expert analysis. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akanda Corp
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2022-03-15 | Interim CEO & Executive Director Ms. Katharyn Field | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.akandacorp.com |
Full time employees - | Website https://www.akandacorp.com | ||
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products. The company was incorporated in 2021 and is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.